BEST will be tied to AGEN2034, an anti-PD-1 antibody for cancer. Credit: rawpixel on Unsplash.

Immuno-oncology firm Agenus is set to introduce Biotech Electronic Security Token (BEST), a new way to fund the development of its cancer drug candidate AGEN2034.

BEST is a blockchain-based digital security offering and said to be the first of its kind in healthcare industry.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Agenus added that the digital token will enable investors to directly invest in single products and will have a limited affect on shareholders’ equity.

BEST will be tied to AGEN2034, an anti-PD-1 antibody currently undergoing a pivotal clinical trial; each token will be linked to a portion of potential future US sales of the product, and can be redeemed once sales commence.

The company is seeking investments of up to $100m via the new financing approach, to support the development, commercialisation, distribution and indication expansion of the drug candidate.

Digital investment group Atomic Capital will manage the investor participation and validation.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData
“By announcing the first of its kind asset backed digital security offering in healthcare, we open the doors for a transformative financing vehicle.”

Agenus chairman and CEO Garo Armen said: “Today, by announcing the first of its kind asset backed digital security offering in healthcare, we open the doors for a transformative financing vehicle.

“We believe this unique structure will pave the way for allowing targeted investment by qualified investors in the development of therapeutic products. This instrument, powered by blockchain technology, enables us to revolutionise the financing of drug development.”

The company expects the new financing model to be adopted by the healthcare industry in the future. However, the digital securities are yet to be approved by regulators, noted Bloomberg.

Agenus is primarily engaged in discovery and development of immunotherapies for cancer. Its pipeline includes multiple early phase programmes.

Last month, the company partnered with Gilead Sciences to drive the development and commercialisation of up to five immuno-oncology (I-O) candidates.

The deal involves $150 in upfront payment, along with approximately $1.7bn in potential future fees and milestones from Gilead.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Imagene’s Oncology Intelligence (OI) Suite has won the Innovation Award for Precision Oncology, for transforming how pharma designs and runs oncology trials. From AI-driven biomarker discovery to smarter patient stratification, see how Imagene is cutting time, cost and risk in cancer drug development.

Discover the Impact